This study was structured to challenge the hypothesis that nano-sized particulates could be molecularly targeted and bound to the prognostic and predictive HER-2/neu cell membrane receptor to elicit detectable changes in ultrasound response from human breast cancer cells. SKBR-3 human breast cancer cells were enlisted to test the efficacy of the particle conjugation strategy used in this study and ultimately, to provide conclusive remarks regarding the validity of the stated hypothesis. A characterization-mode ultrasound (CMUS) system was used to apply a continuum mechanics based, two-step inversion algorithm to reconstruct the mechanical material properties of four cell/agarose test conditions upon three independent test samples. The four test conditions include: Herceptin® conjugated iron oxide nanoparticles bound to cells (HER-con), Herceptin® bound to cells (HER), iso-type matched antibody conjugated iron oxide nanoparticles bound to cells (ISO-con), and Cold Flow Buffer mixed with agarose (CFB). The statistical analysis of these ultrasound results supported the ability to differentiate between HER-2/neu positive SKBR-3 cells that have been successfully tagged with Herceptin® conjugated iron oxide particles to those that have not demonstrated particle binding. These findings serve as promising proof-of-concept data for the development of a quantitative histopathologic evaluation tool directed towards both in situ and in vivo applications. The ultimate goal of this research is to exploit the molecular expression of the HER-2/neu protein to offer rapid, quantitative ultrasound information concerning the malignancy rating of human breast tissue employing tumor targeting nanoparticle based ultrasound contrast agents. When fully developed, this could potentially help 32,000-63,000 women efficiently find their proper treatment strategy to fight and win their battle against breast cancer.
Introduction
The HER-2/neu molecule is a transmembrane receptor tyrosine kinase of the epidermal growth factor receptor (EGF-R) family known as c-erbB-2/neu (1, 2). Studies have shown HER-2/neu overexpression occurs in 15-30% of all breast carcinomas (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . It has been recognized that high levels of HER-2/neu receptor expression is an indicator of poor prognosis in breast cancer patients and serves as a predictive factor in projecting patient response to chemotherapeutics (6). The critical threshold level for HER-2/neu expression has been clinically established as an evaluation greater than 2+ on the HER-2/neu expression grading scale (11). This presents the HER-2/neu protein as a logical target for immunologically-based detection and anti-tumor therapy.
The HER-2/neu proto-oncogene, found on chromosome 17 (3, 4) , encodes a protein and functions as a cell membrane receptor. Normal cells inherently present low levels of HER-2/neu receptors (11) . The HER-2/neu family plays an important role in regulating cell growth, survival, and differentiation in a complex manner, and therefore, its malfunction has the potential for unregulated neoplastic growth. Under normal conditions, the HER-2/neu receptor is responsible for moderating its stimulation through selective ligand binding (10) . Ligand binding to the HER-2/neu receptor complex leads to the activation of intrinsic protein tyrosine kinase activity, triggering a cascade of events that promotes normal cell division and growth.
Anomalous genetic conditions can elicit an oncogenic transformation that results in gene amplification, or increased number of gene copies on a single chromosome. Subsequent 10-to 100-fold increase of the HER-2/neu protein instigates constitutive receptor activation promoting uncontrolled cell growth and imminent tumorgenesis. Although overexpression of the HER-2/neu protein occurs in less than a third of breast cancer patients, positive lymph nodes is the only prognosticator that has been found to be more predictive for clinical outcome (11).
Numerous studies have attempted to quantify the levels of expression of HER-2/neu using immunohistochemical (IHC) assays, fluorescence in situ hybridization (FISH), and trastuzumab (Herceptin®, Genentech, South San Francisco, CA) staining. There is much debate over the clinical feasibility of these tests due to the unsatisfactory sensitivity, cost, reliability, and required expertise (12) (13) (14) (15) (16) (17) (18) . Immunohistochemistry is the most common technique used to evaluate HER-2/neu expression due to its ease of use and relatively low cost. However, the technique suffers from being highly subjective since the numerical scale (0, 1+, 2+, 3+) used for tissue evaluation is based upon the qualitative assessment of cell staining intensities. The criteria used to evaluate cell staining intensities are presented in Table I as defined by the Molecular Pathology Laboratory of the Lombardi Cancer Center at the Georgetown University. Three breast cancer cell lines (SKBR3, MDA-MB-175, and MDA-MB-231), which express 2.4 million, 92,000, and 22,000 HER-2/neu receptor molecules respectively, were used to benchmark the IHC scores for the HER-2/neu expression (1). Studies indicate that HER-2/neu IHC scores of +2 and +3 are associated with breast cancer patients having poor clinical outcomes (2, 5, 6, 8, 10, 11) .
Current IHC methods used for HER-2/neu assessment offer 63-84% sensitivity and 95-98% specificity (19-23), however, these values represent a single observer differentiating between negative (benign: 0/1+ scored tissue) and positive (malignant: 2+/3+ scored tissue) tissue types. Inter-observation studies have demonstrated that pathologists come to complete agreement as low as 9% (20, (24) (25) (26) (27) (28) . In defense of pathologists, this percentage is based on the ability of a group to unanimously score a specimen according to a qualitative universal grading system (Table I) . The inherent subjective nature of histologic grading systems makes if very difficult for a group to agree upon intermediate classifications of disease (i.e., 0/1+, 1+/2+, 2+/3+). One cannot overlook the severe ramifications of inaccurately categorizing tissue biopsies within the inappropriate intermediate classification of disease since histologic grading systems are often used to determine which patients will be administered survival enhancing adjuvant therapy, or in the case of HER-2/neu, predict the patient response to Herceptin® treatment (3, 24).
Characterization-Mode Ultrasound
A proven industrial ultrasound material characterization technology has been adapted to create a new medical ultrasound modality that provides quantitative information regarding the malignancy potential of excised breast tissue. A previous study has demonstrated the feasibility of using this diagnostic system called characterization-mode ultrasound (CMUS), for tissue differentiation or classification determined by the actual mechanical properties of the tissue. This study was based on the hypothesis that malignant and normal tissues inherently possess distinctive shear, elastic, and attenuation properties that allow tissue differentiation (29) (30) (31) .
This approach utilized a mechanical model to reconstruct tissue material properties by curve fitting theoretical and experimental reflection spectra to elicit material property predictions. Transmitting and receiving transducers were set at one oblique angle to gain insight on longitudinal and shear tis-sue/ultrasound wave interactions. These reflections were then captured, gated, and transformed via a Fast Fourier Transform (FFT) to the frequency domain. The CMUS methodology is unique in comparison to other spectral analysis techniques because the spectral parameters are representative of established mechanical properties (29, 30, 32) . Liu et al., The Ohio State University (OSU) , established the potential of utilizing CMUS technology to differentiate the tissue type of biopsy sections using specific mechanical parameters: density (ρ), Lame's constants (λ and µ), thickness (H), and attenuation factors (29, 30) .
The CMUS technology was further developed through the integration of a more robust mechanical model and system hardware configuration to increase the diagnostic sensitivity of the system. These advancements have made it possible to detect mechanical changes contributed by iron oxide nanoparticles targeted towards HER-2/neu receptors upon SKBR-3 cells embedded within an agarose tissue phantom matrix. The well-characterized, clinically utilized, monoclonal antibody (Mab) metastatic breast cancer treatment, Herceptin® (trastuzumab), served as the targeting moiety for the iron oxide nanoparticles. Herceptin® is a humanized IgG that specifically binds to the extra cellular domain of HER-2/neu tyrosine kinase receptors that are found to be overexpressed in a significant percentage of breast cancer patients (33). The following study demonstrates that CMUS technology provides the means for the molecular analysis of breast cancer cells through the detection and quantification of the mechanical contributions induced by tumor targeting Mab conjugated iron oxide nanoparticles.
Materials and Methods

Antibody-to-Nanoparticle Conjugation
The commercially available Mab, Herceptin®, (Genentech, San Francisco, CA) was conjugated to protein G conjugated iron oxide nanoparticles (Miltenyi Biotec, Gladbach, Germany). Miltenyi iron oxide particles were chosen for this study due to the ease of particle separation necessary for the antibody/particle conjugation process mediated by their magnetic properties. Briefly, 100µl protein G conjugated nanoparticles (calculated to be 3.2 × 10 13 particles) were added to 10µg antibody and 480µl buffer (PBS without CaCl 2 and MgCl 2 , Invitrogen, Carlsbad, California). The solution were agitated gently and incubated for 45 minutes to conjugate the constant region of antibodies to protein G. The solution was then placed onto a one Tesla magnet (Master Magnetics, Castle Rock, CO) in a 1.5ml tube overnight. The supernatant was drawn off the following morning and replaced with PBS buffer. This washing step was repeated twice more. The same process was completed for an anti-body isotype-matched to Herceptin® (Sigma-Aldrich, St. Lois, MO). The iso-type matched antibody conjugated particle served as a negative control for this study that provides insight regarding the potential non-specific binding of Herceptin® conjugated particles.
Particle Characterization
Protein G nanoparticles were analyzed on the basis of size, valency (i.e., number of proteins per particle), iron content, and particle concentration. The content of protein G on nanoparticles was quantified using a modified version of the bicinchoninic acid (BCA) assay (34). The assay reagents for the Micro BCA assay were purchased from Pierce Chemical Company (Rockford, Illinois). The concentration of iron in the sample was quantified by modification of the protocol of Riemer et al. (35) . In brief, protein G nanoparticles were dissolved in concentrated HCl for 30 min at 70 °C. A ferrozine and neocuproine-based detection reagent was then used to quantify the amount of iron in samples through a colorimetric comparison to iron chloride standards via an ELx-808 absorption reader (Bio-Tek instruments, Winooski, Vermont) at an excitation wavelength of 490 nm. Dynamic Light Scattering (DLS) was used to size nanoparticles by hydrodynamic diameter using a Zetasizer Nano S Series instrument from Malvern Instruments (Southborough, Massachusetts). Nanoparticle batches were diluted in PBS and sonicated prior to analysis.
Cell Culture
SKBR-3 human breast cancer cells were purchased from ATCC (Mannassas, VA). The cell line was maintained in RPMI-1640 (Cambrex, East Rutherford, New Jersey) supplemented with 10% fetal bovine serum and 1% antimycotic in a 5% CO 2 humidified atmosphere at 37 °C.
Cell Targeting
The cell targeting protocol was initiated once the SKBR-3 cells were at least 70% confluent. Media was aspirated and cells were removed from the bottom of the flask by trypsinization. The trypsin was neutralized with serum containing media and cells and the contents were spun at 1200rpm for 8 minutes to pellet. Media was aspirated and cells were resuspended with approximately 2mL of media and counted for determination of cell concentration on a hemocytometer. Approximately 5 × 10 6 to 1 × 10 7 cells were added per tube to flow tubes. After pelleting the cells (1200 rpm, 8 mins), media was aspirated and resuspended in 100µl cold flow buffer (4 °C; PBS +5% Filtered FBS). Next, primary antibody and conjugates containing primary antibody were added to appropriate tubes (10µg Herceptin® and conjugated nanoparticle solutions obtained by use of above protocol). Tubes were then incubated on ice for 30 minutes. Next, cells were washed with 2mL cold flow buffer and spun to pellet. Cells were aspirated, rinsed along the ring interface between cells and remaining supernatant, and resuspended in 50µl cold flow buffer. Secondary antibody was added to the solutions (mouse anti-human FITC kappa light chain, Biosource International, Camarillo, California, at 50µl per flow tube of 1:50 dilution, made in flow buffer). The solutions were incubated on ice for 30 minutes. Cells were washed with 2mL cold flow buffer, spun to pellet, and then the supernatant was aspirated. Cells were rinsed, and then resuspended in approximately 400µl cold flow buffer for analysis by flow cytometry.
Flow Cytometry and Fluorescent Microscopy
Antibody and nanoparticle-targeted cells were analyzed using a BD FACSCalibur™ (Becton Dickinson, Franklin Lakes, New Jersey). Cells were also imaged using fluorescent microscopy both pre-and post-mixing with agarose by plating 20µl cell solution on a glass slide and covering with a glass cover slip.
Cell Preparation for Ultrasound
After flow cytometric analysis, cell tubes were warmed in a water bath at 45 °C for 4-5 minutes. Meanwhile, glass plates (10.16 × 15.24cm) were warmed in an oven to 55 °C. Square (2 × 2cm), frame-like molds were created using 150µm thick tape (1506CW vinyl seal, Venture Tape Corporation., Rockland, MA) upon the bottom glass plate. The tape was used as an accurate spacer and mold to contain the cells in the agarose matrix. Four molds are created upon each glass bottom plate to accommodate four different test conditions: Herceptin® conjugated particles with cells (HER-con), isotype matched conjugated particles with cells (ISO-con), Herceptin® conjugated cells (HER), and cold flow buffer (CFB) without cells. A volume of 250µl of each appropriate testing condition (HER-con, ISO-con, HER, and CFB) was added to 250µl of warm 1% agarose solution. After a 2-3 minute temperature equilibration period for the cell/agarose solutions, the solutions of each test condition were gently mixed and pipetted into the appropriate tape molds upon the warmed bottom glass plate. The glass plates and cell/agarose solutions were kept above 37 °C to avoid premature solidification of the agarose. A clean blank plate of glass was immediately pressed over the bottom glass plate to displace excess cell/agarose solution from within the tape molds and to con-trol specimen thickness. Precautions were taken to avoid air bubble accumulation within the tape molds. The glass fixture was then clamped with vice grips and sealed with epoxy (Loctite,Henkel Technologies, Rocky Hill, CT).
Characterization-Mode Ultrasound (CMUS): Sample Testing
Although the CMUS system is a non-conventional medical ultrasound modality, the operating procedures follow the same fundamental testing methodology as conventional medical ultrasound techniques. Testing begins with the submerging of the target glass plate sample fixture in a water bath. The aqueous environment serves as an acoustic coupling agent for ultrasound wave propagation. Ultrasound mechanical waves are produced by a pulser (Panametrics, 5052PR, Waltham, MA) and transmitted by unfocused broad band transducers (Panametrics, central frequency 10 MHz, .5" diameter). The waves then interact with the elements of the glass sample fixture (i.e., top glass, tissue phantom, bottom glass) and their reflections are received by the receiver (Panametrics, 5052R) via the transducers, transformed back to electronic pulses, and then are digitized by a waveform digitizer (SignaTec, PDA500M, Corona, California) at a sampling rate of 125MHz. A computer controlled X,Y-coordinate translation system (Velmex 86MM, Bloomfield, NY) was employed to scan the entire surface area of the target sample conditions. The synchronization of the ultrasound software and translational hardware system produced 441 distinct testing points for each testing condition.
For each distinct test point, a time domain plot is generated. In reference to Figure 2 , the relevant portion of the time domain plot resides at the glass/tissue interface (Reflection 1). A software interface program allows this region of the time domain plot to be "gated" or cut out. A Fast Fourier Transform (FFT) is then applied to the gated portion of the time domain plot to produce values of reflection coefficients as a function of frequency. It was necessary to physically level the glass test fixture and optimize the focus of the transducers upon the glass/specimen interface plane prior to scanning each of the four testing conditions.
Characterization-Mode Ultrasound: Data Analysis
The CMUS system used in this study was developed by Dr. Stanislav Rokhlin's research group at The Ohio State University for use in industrial non-destructive-evaluation (NDE) applications. Liu et al. were the first to utilize this technology for use in clinical medicine. The novel technological development unique to this study was the employment of a mechanical model that offers higher accuracy than the previous approach. Liu et al. reconstructed six nondimensional continuum mechanical parameters from a single oblique angle of incidence. The shear and normal components of the oblique transmission wave were used to resolve these parameters (29).
This study employed a continuum mechanics (CM) based model that is predicated on the use of two angles of incidence: normal and oblique (17 deg). Wang et al. established that the reflection\transmission spectrum at a single angle of incidence is not reliable to decouple all six non-dimensional parameters with sufficient accuracy (36) . Additional relations necessary to obtain layer properties can be obtained from both normal and oblique measurement. Lavrentyev and Rokhlin (37) developed an ultrasonic method for the simultaneous determination of all properties of the layer: density, thickness, longitudinal, and shear moduli, and attenuations, using ultrasonic measurements at two angles. A description regarding the theoretical model of ultrasonic wave propagation and the construction of the inversion algorithm used to reconstruct the mechanical parameters will be briefly explained in this manuscript. For explicit details, please refer to reference (36) . The reconstruction of the continuum mechanics parameters for each sample was performed utilizing a mathematical model that incorporates a two-step inversion algorithm and the normal and oblique reflection spectra of the embedded layer. The six mechanical parameters reconstructed by the inversion model are: elastic Lamé moduli λ and µ; thickness h, density ρ, and longitudinal and shear attenuations α l , α t :
Lavrentyev and Rokhlin (37) employed the strategy of solving the six non-dimensional parameters in two distinct steps. The first inversion process calculates three non-dimensional parameters unique to the normal reflection spectrum (37):
where ω 0 = 1MHz for convenience as a normalization factor and V l is the longitudinal velocity in the layer. Z l = ρV l and Z 0 = ρ 0 V l0 correspond to the acoustic impedance of the layer and the substrate respectively, V l0 and ρ 0 are the substrate velocity and density (37) . The parameters defined by Eqn.
[3], are then used in a second inversion step that incorporates the oblique reflection spectrum and solves for three more non-dimensional parameters (37):
where V t is the shear velocity in the embedded tissue layer; where V l0 and V t0 are substrate longitudinal and shear velocities (37) . The relations between dimensional and nondimensional parameters are determined as (37): Figure 3 illustrates the flow chart for the parameter reconstruction process. For each point, elastic Lamé moduli (λ and µ), thickness (h), density (ρ), and longitudinal and shear attenuations (α l , α t ) were calculated.
Results & Discussion
SKBR-3 cells are often used as the 3+ IHC standard for HER-2/neu overexpression (1). To demonstrate the efficacy of the targeting moiety conjugated to the iron oxide nanoparticle, bright field and fluorescence microscopy images were taken of SKBR-3 cells with bound Herceptin® conjugated nanoparticles (HER-con), iso-type matched antibody conjugated nanoparticles (ISO-con), and Herceptin® (HER). The ISO-con and HER conditions were used as negative and positive controls respectively. A FITC tagged secondary antibody directed to the kappa light chains of the primary antibody provided the fluorescent signature for bound HER-2/neu receptors. The microscopy images can be seen in Figure 4 . Similar fluorescent intensities were demonstrated for both the HER and HER-con conditions and only artifact [2]
[3]
[4]
fluorescence was visible for the ISO-con control condition. The flow cytometry data supports the elevated fluorescent intensities for the Herceptin mediated binding conditions in respects to the iso-type matched control.
It should be noted that a control experiment was performed utilizing MDA-MB-231 cells. MDA cells are a metastatic breast cancer cell line that inherently expresses HER-2/neu at a negligible amount (∼5%); significantly less than that of the SKBR-3 cells. Pictures were taken of MDA cells conjugated with the relevant experimental conditions (HER, HERcon, ISO-con), however, these images were not included since there was no detectable fluorescence.
In this study, three independent cell samples with four different testing conditions were created. Values for each of the six mechanical parameters were reconstructed for each of the 441 points scanned per test condition. Of the six mechanical parameters, density (ρ), and the elastic Lamé moduli (λ and µ) were found to have a relationship with particle concentration. Previous experiments were performed in which nanoparticulates were distributed homogeneously in an agarose matrix at varying particle concentrations (0 particles/ml, 7 × 10 11 particles/ml, 7 × 10 12 particles/ml, 1.4 × 10 13 particles/ml) in a cell-free solution to generate nanoparticle dose response curves for the CMUS system (data not shown). The curves illustrated the linear effects of nanoparticulate concentration in respects to both matrix density and stiffness in a controlled, uniform system. By combining the elastic Lamé moduli as shown, (λ +2 µ), a representation of stiffness can be calculated. Table IV shows the percent differences normalized to the CFB condition for each sample.
Table IV indicates that the HER-con condition consistently presents approximately double the percent difference for mean density and stiffness compared to the HER and ISOcon conditions. An analysis of variance (ANOVA) was performed to evaluate the statistical significance of the data from each test condition (Data not shown). A Tukey Honestly Significant Difference (HSD) Post Hoc Test was also used to compare all possible pairs of test condition means to determine which differences in the test condition means were statistically different. (Data not shown) This post hoc test finds the numeric difference between means that is statistically different at the 0.05 level of significance. It achieves this without inflating the alpha error rate, which would happen if a series of t-tests were used to identify the differences. Minitab (Minitab Inc., State College, PA) was used to calculate the ANOVA for the sample data as well as the post hoc test.
The ANOVA and Tukey post test statistically prove that the HER and ISO-con conditions were statistically indistinguishable from each other. The statistical analysis did also indicate that the data points corresponding to the CFB condition, the HER and ISO-Con conditions, and the HER-con condition were distinct from each other.
These findings support the hypothesis that the highest particle concentration was found in the HER-con condition since this condition demonstrated the highest values for density and stiffness. Since the HER and ISO-con conditions were statistically indistinguishable, it would suggest that that negligible particle binding was observed in the ISO-con condition and therefore the SKBR-3 cells did not provide signifi- cant non-specific binding opportunity for iso-type matched antibody conjugated nanoparticles. Further experiments that quantify the amount, if any, of non-specific binding of the iso-type matched antibody conjugated particle, will be necessary to evaluate the exact relationship between HER-con and ISO-con mechanical properties and the HER-2/neu receptor expression of SKBR-3 cells. The additional studies will also include extra test conditions (e.g., non-conjugated SKBR-3 cells) to elucidate the mechanical effects (e.g., anti- body crosslinking) of the Herceptin® antibody to the cell suspension since the HER condition consistently relinquished higher mechanical properties than that of the ISOcon condition. In order to establish the CMUS system as a viable option to IHC evaluation, correlation data must also be created for each IHC score (0, 1+, 2+, 3+) relative to the mechanical response reconstructed from test sample conditions. This could be achieved through dose response experiments that utilize the three benchmark breast cancer cell lines (SKBR3, MDA-MB-175, and MDA-MB-231).
Ultrasound Contrast Agents for Tumor Detection 633
In conclusion, this study demonstrates that characterizationmode ultrasound is capable of detecting the presence of nanoparticle mechanical contrast agents that have been targeted to a specific tumor molecular marker. Quantification of the expression of HER-2/neu receptors upon the surface of SKBR-3 cells is provided by the CMUS system through the correlation of the mechanical response from test samples to the concentration of nanoparticle contrast agents. The current pool of data is insufficient to provide sensitivity and specificity values for the CMUS system; however, the aim of this study is to exceed the 63-84% sensitivity and 95-98% specificity produced by current IHC techniques. More importantly, the CMUS system can potentially provide the ability to define intermediate classifications of disease that may optimize the therapeutic regime administered to a patient. This feature offers a significant advantage over current IHC techniques.
The data presented herein provides positive proof-of-concept data for the development of a quantitative molecular analysis diagnostic system for in situ and in vivo applications. Currently this technology is being developed to accommodate the HER-2/neu expression quantification for fresh frozen human tissue biopsies. This in situ case presents a significant challenge for the CMUS system since tissue is a granular, heterogeneous material, very dissimilar to the homogenous cell/agarose matrix of this study. To accommodate the additional complexity required for the reconstruction of the material properties of tissue, focused transducers will be employed. Focused transducers can provide a significantly smaller spot size that will enable the analysis and reconstruction of tissue properties on a scale relevant to bound nanoparticle contrast agents upon diseased tissue. The utilization of focused transducers presents the need to modify the current CMUS reconstruction algorithms to adapt from the capture of plain wave reflections to reflections from a focused incident beam of ultrasound.
Currently, a C-scan ultrasound approach is being developed as a proof-of-concept investigation for the next generation CMUS system. Preliminary results in the form of C-scan images suggest that focused transducers are capable of resolving the presence of nanoparticulates bound to the HER-2/neu surface receptors of biopsy tissue. Quantitative molecular analysis of the expression of HER-2/neu receptors has been achieved through image analysis techniques, however insufficient data has been collected to imply statistical significance and hence will be presented in future publications. Further developments of the C-scan approach as well as the continued advancement of the CMUS algorithms hold promise for in situ and in vivo applications; however, no in vivo testing has commenced at this time.
